Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer.

[1]  J. Milovanović,et al.  Interleukin-6 and interleukin-8 serum levels in prognosis of hormone-dependent breast cancer. , 2019, Cytokine.

[2]  T. Tammela,et al.  Resistin and interleukin 6 as predictive factors for recurrence and long-term prognosis in renal cell cancer. , 2017, Urologic oncology.

[3]  M. Okumura,et al.  IL‐6 Secreted from Cancer‐Associated Fibroblasts Mediates Chemoresistance in NSCLC by Increasing Epithelial‐Mesenchymal Transition Signaling , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  Y. Kukita,et al.  Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer. , 2016, Lung cancer.

[5]  O. Arrieta,et al.  Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial , 2016, Targeted Oncology.

[6]  Caicun Zhou,et al.  Strategies to Improve Outcomes of Patients with EGRF‐Mutant Non–Small Cell Lung Cancer: Review of the Literature , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  David Gilligan,et al.  Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. , 2015, The Lancet. Oncology.

[8]  L. Love-Homan,et al.  Upregulated interleukin‐6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma , 2015, Molecular oncology.

[9]  Yijun Tian,et al.  Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer , 2015, Journal of Hematology & Oncology.

[10]  Jeremy J. W. Chen,et al.  Dynamic Plasma EGFR Mutation Status as a Predictor of EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Adenocarcinoma , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[12]  Anne-Pascale Meert,et al.  Management of EGFR mutated nonsmall cell lung carcinoma patients , 2015, European Respiratory Journal.

[13]  Bernard Klein,et al.  Interleukin-6 as a Therapeutic Target , 2015, Clinical Cancer Research.

[14]  Guotong Xu,et al.  Epithelial phenotype as a predictive marker for response to EGFR‐TKIs in non‐small cell lung cancer patients with wild‐type EGFR , 2014, International journal of cancer.

[15]  Y. Hu,et al.  Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer , 2014, BMC Cancer.

[16]  Koichi Goto,et al.  Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. , 2014, The Lancet. Oncology.

[17]  F. Hirsch,et al.  The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non–small cell lung cancer , 2014, Cancer.

[18]  Yong He,et al.  Metformin Sensitizes EGFR-TKI–Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal , 2014, Clinical Cancer Research.

[19]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Jeongseon Kim,et al.  Prognostic Role of Interleukin-6, Interleukin-8, and Leptin Levels According to Breast Cancer Subtype , 2013, Cancer research and treatment : official journal of Korean Cancer Association.

[21]  Chien-Jen Chen,et al.  Circulating interleukin‐6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy , 2013, International journal of cancer.

[22]  Z. Duan,et al.  Interleukin-6 signaling pathway in targeted therapy for cancer. , 2012, Cancer treatment reviews.

[23]  Qinghua Xu,et al.  Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is effective as first‐line treatment of advanced non‐small‐cell lung cancer with mutated EGFR: A meta‐analysis from six phase III randomized controlled trials , 2012, International journal of cancer.

[24]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[25]  G. Scagliotti,et al.  Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[27]  C. Rancourt,et al.  Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients , 2011, BMC Cancer.

[28]  G. Giaccone,et al.  American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  N. Altorki,et al.  TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer , 2010, Proceedings of the National Academy of Sciences.

[30]  T. Ohira,et al.  Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non–Small Cell Lung Adenocarcinoma , 2010, Clinical Cancer Research.

[31]  N. Ferrara,et al.  Autocrine VEGF Signaling Synergizes with EGFR in Tumor Cells to Promote Epithelial Cancer Development , 2010, Cell.

[32]  J. Abbruzzese,et al.  F1000 highlights , 2009, JAMA.

[33]  Josep Tabernero,et al.  The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents , 2007, Molecular Cancer Research.

[34]  L. Ellis,et al.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  K. Kiura,et al.  Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations. , 2018, Biochemical and biophysical research communications.

[36]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.